NCT00907959View on ClinicalTrials.gov

A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

July 31, 2015

Conditions
Metastatic Breast Cancer
Interventions
DRUG

BZL101

Oral BZL101 20 grams/day (10 grams BID).

Trial Locations (1)

77030

M.D. Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Bionovo
All Listed Sponsors
lead

Bionovo

INDUSTRY

NCT00907959 - A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter